Core Viewpoint - The announcement from the National Medical Insurance Administration indicates the commencement of the sixth batch of centralized procurement for high-value medical consumables in Tianjin, which includes 12 types of medical consumables used in specific surgical procedures [1] Group 1: Procurement Details - The sixth batch of procurement includes drug-coated balloons and urological intervention consumables, specifically targeting treatments for vascular stenosis and urinary system stones [1] - This procurement follows five previous batches that covered a wide range of medical consumables, including coronary stents, artificial joints, spinal orthopedic products, intraocular lenses, sports medicine items, cochlear implants, and peripheral vascular stents [1] Group 2: Treatment Areas - The previous procurement batches have broadly encompassed treatment areas such as cardiology, orthopedics, ophthalmology, otolaryngology, and vascular surgery [1]

1月13日11时30分，第六批国家组织高值医用耗材集采首轮报价唱标结束。根据采购规则，首轮未中选 的企业，有机会根据采购规则进行第二轮"复活"报价，引导更多企业以适宜价格供应，丰富临床选择。 （文章来源：新华社） ...

Core Viewpoint - The sixth batch of national organized high-value medical consumables procurement has commenced, with significant participation from 227 companies submitting bids for 496 products, indicating a robust competitive landscape in the medical supplies sector [1] Group 1: Procurement Details - The procurement event took place in Tianjin, starting with the submission of bidding materials at 7:30 AM and the opening of bids at 9:30 AM, expected to last until the afternoon [1] - This round of procurement includes two major categories: drug-coated balloons and urological intervention, covering 12 types of medical consumables used in vascular stenosis and urinary system stone surgeries [1] Group 2: Selection Rules and Mechanisms - The selection rules for this round have been optimized, introducing the concept of "anchor price," where the higher value between 65% of the arithmetic average price of valid bids and the lowest bid price will be considered [1] - A multi-revival mechanism has been further refined, allowing non-selected companies to compete for selection again under specific rules, which is expected to enhance participation enthusiasm among enterprises [1] Group 3: Previous Procurement Rounds - Prior to this round, five batches of national organized high-value medical consumables procurement have been conducted, covering a wide range of medical fields including cardiology, orthopedics, ophthalmology, ENT, and vascular surgery [1]

Core Viewpoint - The sixth batch of national organized high-value medical consumables centralized procurement is taking place in Tianjin, with participating companies submitting their application materials on January 13 at 7:30 AM [1] Group 1: Procurement Details - This procurement includes two categories of medical consumables: drug-coated balloons and urological intervention, comprising a total of 12 types of consumables [1] - These consumables are used for procedures related to vascular stenosis and urinary system stones [1] Group 2: Previous Procurement Batches - Prior to this, five batches of national organized high-value medical consumables procurement have been conducted, covering items such as coronary stents, artificial joints, spinal orthopedic products, artificial lenses, sports medicine, cochlear implants, and peripheral vascular stents [1] - The previous procurement efforts have broadly covered treatment areas including cardiology, orthopedics, ophthalmology, otolaryngology, and vascular surgery [1]

1月13日，第六批国家组织高值医用耗材集中带量采购即将在天津开标，本次集采纳入药物涂层球囊、 泌尿介入两大类12种医用耗材，这两类耗材分别用于血管狭窄、泌尿系统结石手术等。投标企业于7点 30分陆续入场递交申报材料。9点半左右将开始现场开标，集采结果将于今天傍晚公布。 （文章来源：央视新闻） 此前，医保部门已开展五批国家组织高值医用耗材集采，分别纳入冠脉支架、人工关节、脊柱类骨科、 人工晶体、运动医学、人工耳蜗、外周血管支架等耗材，广泛覆盖心内科、骨科、眼科、耳鼻喉、血管 外科等治疗领域。 ...

Core Viewpoint - This week, there are two new stocks available for subscription: one on the Beijing Stock Exchange and one on the Sci-Tech Innovation Board [1][6]. Group 1: Aishalun - Aishalun is the largest manufacturer of medical care pads in China [2][7]. - The issue price of Aishalun is 15.98 yuan per share, with a price-to-earnings ratio of 14.99 times [3][8]. - Aishalun focuses on the medical health sector, specializing in the research, production, and sales of disposable medical consumables for rehabilitation and medical protection [3][8]. - The company has shown rapid growth, with revenues of 574 million yuan, 575 million yuan, and 692 million yuan from 2022 to 2024, and net profits of 63 million yuan, 67 million yuan, and 81 million yuan for the same years [3][8]. - For 2025, Aishalun's management forecasts a revenue growth of 28.65% to 35.89% and a net profit growth of 10.63% to 22.01% [3][8]. Group 2: Hengyunchang - Hengyunchang is a leading supplier of core components for semiconductor equipment in China [4][9]. - The public offering will consist of 16.93 million shares, with a maximum subscription limit of 4,000 shares for online investors [4][9]. - Hengyunchang is recognized as having the highest market share among domestic plasma RF power system manufacturers in 2024 [4][9]. - The company has established strategic partnerships with major semiconductor equipment manufacturers, becoming a core supplier in critical processes such as film deposition and etching [4][9]. - From 2022 to 2024, Hengyunchang's revenues were 158 million yuan, 325 million yuan, and 541 million yuan, with net profits of 26 million yuan, 80 million yuan, and 142 million yuan [4][9]. - For 2025, the company anticipates a revenue decline of 4.69% to 9.58% and a net profit decline of 19.54% to 28.21% [4][9]. Group 3: Market Overview - In 2025, a total of 19 new stocks will be listed on the Sci-Tech Innovation Board, bringing the total number of companies to 600 [5][10]. - All 19 new stocks experienced price increases on their first trading day, with an average increase of 244.37%, and 18 of them saw gains exceeding 100% [5][10]. - The most recent listing was Qiangyi Co., a leading domestic semiconductor probe card company, which had an issue price of 85.09 yuan per share and a first-day increase of 165.61%, resulting in a profit of 70,500 yuan per subscription [5][10].

Group 1 - Shaanxi Tourism officially listed on the Shanghai Stock Exchange, marking the first IPO of 2026, with a first-day increase of 64.10% and a single ticket profit of approximately 26,000 yuan [1] - Next week, two new stocks will be available for subscription: Aisheren, a leading medical dressing company, and Hengyun Chang, a key supplier of semiconductor equipment core components [1][3] - Aisheren specializes in disposable medical consumables for rehabilitation and medical protection, with a strong competitive position in the medical care pad market and stable partnerships with international brands like Medline Group [5][1] Group 2 - Aisheren's forecast for 2025 indicates a net profit of 89.29 million to 98.48 million yuan, representing a year-on-year growth of 10.63% to 22.01% [5][6] - Projected revenue for Aisheren in 2025 is between 889.82 million and 939.87 million yuan, reflecting an increase of 28.65% to 35.89% compared to 2024 [6] - Hengyun Chang is a leading domestic supplier of semiconductor equipment core components, focusing on plasma RF power systems and has achieved mass delivery to major semiconductor equipment manufacturers [1][8] Group 3 - Hengyun Chang's forecast for 2025 shows a net profit of 102 million to 114 million yuan, with a year-on-year decline of 28.21% to 19.54% [8] - Projected revenue for Hengyun Chang in 2025 is estimated to be between 488.99 million and 515.43 million yuan, indicating a decrease of 9.58% to 4.69% compared to 2024 [8] - The company has developed second and third-generation products that support advanced process nodes of 28nm and 7-14nm, respectively, achieving international advanced levels [1]

Core Viewpoint - The article discusses the upcoming IPOs of two companies, Aisheren and Hengyun Chang, highlighting their business focus, financial performance, and market positions. Group 1: Aisheren - Aisheren is the largest manufacturer of medical care pads in China, focusing on disposable medical consumables for rehabilitation and medical protection [2][7] - The IPO price for Aisheren is set at 15.98 CNY per share, with a price-to-earnings ratio of 14.99 [2][7] - Aisheren's revenue for 2022, 2023, and 2024 is projected to be 574 million CNY, 575 million CNY, and 692 million CNY, respectively, with net profits of 63 million CNY, 67 million CNY, and 81 million CNY [2][7] - The company forecasts a revenue growth of 28.65% to 35.89% and a net profit growth of 10.63% to 22.01% for 2025 [2][7] Group 2: Hengyun Chang - Hengyun Chang is a leading supplier of core components for semiconductor equipment, focusing on plasma RF power systems and related technologies [3][8] - The company plans to issue 16.93 million shares, with a maximum subscription limit of 4,000 shares for online investors [3][8] - Hengyun Chang's revenue for 2022, 2023, and 2024 is projected to be 158 million CNY, 325 million CNY, and 541 million CNY, respectively, with net profits of 26 million CNY, 80 million CNY, and 142 million CNY [3][8] - The company anticipates a revenue decline of 4.69% to 9.58% and a net profit decline of 19.54% to 28.21% for 2025 [3][8] Group 3: Market Context - In 2025, a total of 19 new stocks are expected to be listed on the Sci-Tech Innovation Board, bringing the total number of companies to 600 [4][9] - All 19 new stocks listed in 2025 experienced price increases on their first trading day, with an average increase of 244.37%, and 18 of them saw gains exceeding 100% [4][9] - The most recent listing, Qiangyi Co., had an IPO price of 85.09 CNY per share and a first-day increase of 165.61%, resulting in a profit of 70,500 CNY for a single subscription [4][9]

制图 郜婕 该基金不仅是杭州地区首只医药主题的AIC试点基金，也是2026年首只成功备案的AIC试点基金，标志 着金融资本与区域产业战略的深度融合进入新阶段。 AIC试点基金是由中国商业银行设立的金融资产投资公司（Asset Investment Company，简称AIC）发起 并管理的专项投资基金，核心目标是通过市场化、法治化方式开展债转股和战略性股权投资，助力企业 优化资产负债结构、推动产业升级。本次落地的"产融浙药中瀛扶摇（杭州）股权基金"，在浙江省委金 融办、省国资委、省金融监管局及杭州市委金融办等部门的指导与支持下，由浙江省国贸集团、高新金 投等省区两级国有资本运作平台共同设立，实现了政策资源与金融资本的高效对接。 本报讯（记者 黄宇翔 实习生 郜婕）新年伊始，杭州金融市场迎来创新试点新成果。1月6日，由中银金 融资产投资有限公司联合中国银行浙江省分行、杭州市分行共同推动的"产融浙药中瀛扶摇（杭州）股 权基金"正式在中国证券投资基金业协会完成备案，首期规模5亿元。 据了解，作为杭州地区2026年首只备案的AIC试点基金，该基金将紧密围绕浙江省国贸医药板块的战略 规划，重点投资杭州市滨江区及全省范围 ...

Core Viewpoint - Dabo Medical (002901) reported a decline in stock price and mixed capital flow data, indicating potential investor caution despite strong financial performance in recent quarters [1][2]. Financial Performance - For the first three quarters of 2025, Dabo Medical achieved a main operating revenue of 1.876 billion yuan, a year-on-year increase of 22.69% [2]. - The net profit attributable to shareholders reached 425 million yuan, reflecting a significant year-on-year growth of 77.03% [2]. - The non-recurring net profit was 346 million yuan, up 63.99% year-on-year [2]. - In Q3 2025 alone, the company reported a main operating revenue of 666 million yuan, a 17.82% increase compared to the same quarter last year [2]. - The net profit for Q3 2025 was 180 million yuan, showing a year-on-year increase of 77.49% [2]. - The non-recurring net profit for Q3 2025 was 123 million yuan, up 38.44% year-on-year [2]. - The company's debt ratio stands at 24.53%, with an investment income of 5.81 million yuan and financial expenses of -23.87 million yuan [2]. - The gross profit margin is reported at 71.23% [2]. Capital Flow - On January 7, 2026, Dabo Medical's stock closed at 49.48 yuan, down 1.61%, with a turnover rate of 0.68% and a trading volume of 19,500 hands, resulting in a transaction amount of 97.09 million yuan [1]. - The capital flow data for January 7 indicates a net outflow of 10.69 million yuan from main funds, accounting for 11.02% of the total transaction amount [1]. - Retail investors contributed a net inflow of 8.29 million yuan, representing 8.54% of the total transaction amount [1].